Workflow
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
ALLRAllarity Therapeutics(ALLR) Newsfilter·2025-01-30 13:00

Boston (January 30, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, has filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC") regarding its agreement in principle with the SEC staff to resolve the previously disclosed SEC investigation. The settlement relates to the Company's disclosures, ...